37.Issue 05 may 21 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 08, Issue : 05, May – 2021

Title:

37.A REVIEW ON INNOVATIVE AND NOVEL STRATEGY-FLOATING MICROSPONGES

Authors :

Indu Thakur* and Dr. Neelam Sharma

Abstract :

Gastroretentive drug delivery system is a novel method for making the control release drug delivery system. Floating or Gastroretentive drug delivery system holds the advantage of both oral delivery and controlled delivery. Many control release formulations are developed with this method. Most useable and efficient technique is floating microsponges. The Microsponges Delivery System is an original polymeric system consisting of porous microspheres. They are tiny sponge like spherical particles. Microsponges having a countless of interconnected size ranging voids of particle from 5-150 µm. This Microsponges floats on the aqueous fluid of stomach and Releases the medicament for prolonged period of time. For those drugs whose half life is too short. Thus, beneficial for increasing their half life and also increase their bioavailability. These microsponges have more surface area so remain float on an aqueous media. Microsponges are prepared by several methods utilizing quasi emulsion system diffusion or by liquid– liquid suspension polymerization system. Thus this is a useful method.
Key Words: FDDS, Microsponges, Quasi-emulsion solvent diffusion method, Liquid- liquid suspension polymerization , Gastrointestinal system.

Cite This Article:

Please cite this article in press Indu Thakur* and Dr. Neelam Sharma., A Review On Innovative And Novel Strategy-Floating Microsponges.., Indo Am. J. P. Sci, 2021; 08(05).

Number of Downloads : 10

References:

1. Joyti, Kumar Sandeep; floating microsponges gastroretentive drug delivery system, European journal of pharmaceutical medical research. , ejpmr 2019,6(7) 150-157
2. Soppimath, K.S. kulkarni, A.R. Rudzincki, W.E. Aminabhavi, T.M. Microsphere as floating drug delivery system to increase the gastric residence of drugs. Drug Metab Rev, 2001; 33: 149-60.
3. Garg. R, Gupta G.D., Progress in controlled gastroretentive delivery system Trop. J. Pharm. Res, 2008; 7(3): 1055-66.
4. Hwang, S.J., Park, H., Park, K., 1998. Gastric retentive drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 15, 243–284.
5. Streubel. J, Siepmann R.B., Floating matrix tablet based on low density foam powder. European journal of pharmaceutical sciences, 2002; 18: 37-45.
6. Moe¨s, A.J., 1993. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carrier Syst. 10, 143–195.
7. Streubel. J, Siepmann R.B., Floating matrix tablet based on low density foam powder. European journal of pharmaceutical sciences, 2002; 18: 37-45.
8. Joseph. N.J., Laxmi. S., Jayakrishnan. A., A floating type oral dosage form for piroxicam based on hollow microspheres; in vitro and in vivo evaluation in rabbits, J. Control Release, 2002; 79: 71-79.
9.Menon A, Ritschel WA, Sakr A. Development and evaluation of a monolithic floating dosage form for furosemide. J Pharm Sci, 1994; 83: 239-245.
10. Kawashima Y, Niwa T, Takeuchi H, Hino T, Ito Y. Hollow microspheres for use as floating controlled drug delivery system in stomach. J Pharm Sci, 1992; 81: 135-40.
11. Ichikawa M, Watanabe S, Miyake Y. A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with para amino benzoic acid and isosorbide dinitrate as model drugs. J Pharm Sci, 1991; 80: 1153-56.
12. Sarawade A, Ratnaparkhi MP, Chaudhari S. Floating drug delivery system: an overview, International Journal of Research and Development in Pharmacy and Life Sciences. 2014; 3(5):1106-1115.
13. Rouge, N., Buri, P. and Doelker, E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. International Journal of Pharmaceutics, 1996; 136(1-2): 117-39.
14. Goole, J., Vanderbist, F. and Amighi, K. Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms. International Journal of Pharmaceutics, 2007; 334(1): 35-41.
15. Fell J.T., Whitehead, L. and Collett, J.H. Prolonged gastric retention: using floating dosage forms. Pharmaceutical Technology, 2000; 24(3): 82-90.
16. Dave, B.S., Amin, A.F. and Patel, M.M. Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. Aaps Pharm Sci Tech, 2004; 5(2): 77-82.
17. Rajinikanth, P.S., Balasubramaniam, J. and Mishra, B. Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. International Journal of Pharmaceutics, 2007; 335(1): 114-22.
18. Matharu, R.S. and Sanghavi, N.M. Novel drug delivery system for captopril. Drug Development and Industrial Pharmacy, 1992; 18(14): 1567-74.
19. Sarojini S, Manavalan R. An overview on various approaches to gastroretentive dosage form, International Journal of Drug Development and Research. 2012. 4(1):01-13.
20. Arora S, Ali J, Ahuja A, Khar KR, Babopota S. Floating drug delivery system: A review, AAPS pharm Sci Tech.2005; 6(3):372-390.
21. Narang N. An updated review on: floating drug delivery system (fdds), International Journal of Applied Pharmaceutics. 2011; 3(1):1-7.
22. Shivakumar HN et al, Design and evaluation of controlled onset extended release multiparticulate systems for chronotherapeutic delivery of ketoprofen. Indian J Pharm Sci, 2006; 68(1): 76-82.
23. Sharma S et al, Low Density multiparticulate system for pulsatile release of meloxicam.
Int J Pharm, 2006; 313(1): 150-8.
24. Embil K et al, The microsponge_ delivery system (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul, 1996; 13: 575-88.
25. Sharma R et al, Polymeric nanosponges as an alternative carrier for improved retention of Econazole nitrate onto the skin through topical hydrogel formulation. Pharm Dev Technol, 2011; 16(4): 367-76.
26. Nacht S et al, The microsponge: a novel topical programmable delivery system. In: David WO, Anfon HA, editors. Topical drug delivery systems. Volume 42 Marcel Dekker; New York, 1992; 299-25.

27. Baumgartner S, Kristel J, Vreer F, Vodopivec P, Zorko B. Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int J Pharm, 2000; 195: 125-35.
28. Mantry Shubhrajit, Bagchi Arnab, Das Sujit, Das Sudip, Microsponge as A Novel Stratergy of Drug Delivery System, Universal Journal of pharmaceutical science and research, 2015; 1(1):32-38.
29. Kumar Jaya raja, Muralidharan Selvadurai and Parasuraman Subramani, Evaluation of Antifungal Activity of Sustained Release Microsponge Enriched Fluconazole Gel for Penile Candidiasis in Male Rats, International Journal of PharmTech Research, 2014;6(6):1888-1897
30. Avhad Pawan S. and Patil Prashant B., A New Era In Topical Formulations – Microsponge Drug Delivery System International Journal Of Pharmaceutical Science And Research, 2016; 7(7):2756-2761.
31. Muralidharan Selvadurai, Kumar Jaya raja, Ramasamy Sanggetha, Microsponges Enriched Gel (MEGs): A Novel Strategy for Opthalmic Drug Delivery System Containing Ketotifen, Journal of Pharmaceutical Science. & Research 2013; 5(4):97–102.
32. D’souza JI et al, Microspongic delivery of fluconazole for topical application. Indo-Japanese Int Conf Adv Pharm Res Technol, 2004; 456: 76-81.
33. Partibhan KG et al, Microsponges role in Novel drug delivery. Int J Pharm Res Dev, 2011; 3(4): 117-1258.
34. Jelvehgari M et al, A: The microsponge delivery system of benzoyl peroxide: Preparation, characterization and release studies. International Journal of Pharmaceutics, 2006; 308: 124-32.
35. Guyot M. et al, Microspheres- Preparation and physical characteristics. Int J Pharma, 1998; 175: 61-74.
36. Vikrant K et al, Microparticles: a novel approach to enhance the drug delivery – a review, IJPRD, 2011; 3(8): 170- 83.
37. Parthiban KG et al, Microsponge role in novel drug delivery system. International journal of pharmaceutical research and development, 2011; 3(4): 117-25.
38. Comoglu T et al, Preparation and in vitro evaluation of modified release ketoprofen microsponges. ll Farmaco, 2003; 58: 101-6.
39. D‟souza J.I., More H.N. Topicalanti-inflammatory gels of flucinolone acetonide entrapped in eudragit basedmicrosponge delivery system. Res JPharm Technol, 2008; 1(4): 502-6.
40. Grochowicz M et al, Preparation and characterization of porous polymeric microspheres obtained from multifunctional methacrylate monomers. J Polymer Sci, 2008; 46: 6165-74. Christensen MS, Natch SJ. Invest. Dermato, 1983; 69: 282.
41. Parthiban KG et al, Microsponge role in novel drug delivery system. International journal of pharmaceutical research and development, 2011; 3(4): 117-25.
42. Jelvehgari M et al, The microsponge delivery system of benzoyl peroxide: Preparation, characterization and release studies. Int J Pharma, 2006; 308: 124-32.
43. N.H, Aloorkar et al, Microsponge As Innovative Drug Delivery System, International Journal of Pharmaceutical Sciences and Nanotechnology, April –June 2012; 5-1.
44. Martin A. et al, Physical Pharmacy- Physical Chemical Principles in Pharmaceutical Sciences. 3rd Ed, 1991; 527.
45. Emanuele AD et al, Preparation, Characterization and Drug Release from Thermo responsive Microspheres Int J Pharma, 1995; 237-42.
46. Kaity S et al, Microsponge: A novel strategy for drug delivery system, J Adv Pharm Technol Res, 2010; 1(3): 283-90.
47. Shyam SM et al, Novel approach: microsponge drug delivery system, Int J Pharma Sci Res, 2012; 3(4): 967-80.
48. Srivastava R et al, Micosponges: a futuristic approach for oral drug delivery, Expert Opin Drug Deliv, 2012; 9(7): 863-8.
49. D’souza JI, Masvekar RR, Pattekari PP and Pudi SR: 1st Indo-Japanese International Conference on advances in Pharmaceutical research & Technology, Mumbai, India, 2005; 25-29.
50. Rajeshree M et al, Microsponges for the topical drug delivery system. International Journal of Pharm & Tech, 2014; 5: 2839-51.
51. Iwai S, Sawa Y et al, Novel tissue-engineered biodegradable material for reconstruction of vascular wall. Ann. Thorac. Surg, 2005; 80(5): 1821-27.
52. Barkai A et al, Polyacrylate (Eudragit retard) microsphere for oral controlled release of nifedipine. I. Formulation design and process optimization. Drug Dev Ind Pharm, 1990; 16: 2057-75.
53. Khopade A et al, “The Microsponge”. Eastern Pharmacist, 1996; 49-53.
54. Embil VP. OTC External analgesic cream/topical analgesic-antiinflammatory, counterirritant utilizing the Microsponge Delivery System (MDS) for controlled release of actives. Patent Application No: 0101058.6. UK: 2000.
55. Kawashima Y et al, Control of Prolonged Drug Release and Compression Properties of Ibuprofen Microsponges with Acrylic Polymer, Eudragit RS, by changing their Intraparticle Density. Chem Pharm Bull, 1992; 40: 196-01.
56. OrluM et al, Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges. Int J Pharm, 2006; 318: 103-17.
57. Chen G et al, A Biodegradable Hybrid Sponge Nested With Collagen Microsponges. J Biomed Mater Res, 2000; 51: 273-9.
58. Kanematsu A, Marui A, Yamamoto S, Ozeki M, Hirano Y, Yamamoto M, et al. Type I collagen can function as a reservoir of basic fibroblast growth factor. J Control Release, 2004; 94: 281-92.
59.Chen G et al, Culturing of skin fibroblasts in a thin PLGA–collagen hybrid mesh. Biomaterials, 2005; 26: 2559-66.
60. Iwai S, Sawa Y, Taketani S, Torikai K, Hirakawa K, Matsuda H. Novel Tissue-Engineered Biodegradable Material for Reconstruction of Vascular Wall. Ann Thorac Surg, 2005; 80: 1821-7.
61. Goodey A., Lavigne J., Savoy S., Rodriguez M., Curey T., Tsao A., Simmons G., Wright J., Yoo S., Sohn Y., Anslyn E., Shear J., .Neikirk D., McDevitt J., J Am Chem Soc, 2001; 123: 2559–70.
62. Jokerst J., Raamanathan A., Christodoulides N., Floriano P., Pollard A., Simmons G., Wong J., Gage C., Furmaga W., Redding S., McDevitt J. Biosens Bioelectron, 2009; 24: 3622–29.
63. Ali M., Kirby R., Goodey A., Rodriguez M., Ellington A., Neikirk D., McDevitt J., Anal Chem, 2003; 75: 4732– 4739.
64. Jokerst J., McDevitt J,. Nanomedicine, 2010; 5: 143–55.